The Global Huntington's Disease Treatment Market size is expected to reach $805.1 million by 2031, rising at a market growth of 9.0% CAGR during the forecast period.
The Asia-Pacific region's nations are investing in expanding and modernizing its hospitals, clinics, and specialized treatment facilities. Better facilities and access to healthcare enable HD patients to receive sophisticated treatment choices, interdisciplinary care, and early diagnosis. Consequently, the Asia pacific region would acquire nearly 25% of the total market share by 2031. Genetic diversity within the Asia Pacific region provides unique opportunities for studying Huntington’s Disease genetics, disease variants, and population-specific factors influencing disease progression.
Huntington’s disease is caused by a mutation in the HTT gene, which produces an abnormal form of the huntingtin protein. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Additionally, Healthcare expenditure encompasses funding allocated to biomedical research, including neurodegenerative diseases like Huntington’s disease. Furthermore, investments in healthcare infrastructure, such as specialized clinics, research centers, and laboratory facilities, are essential for advancing HD research and treatment. Therefore, rising healthcare expenditures and investments are propelling the market’s growth.
However, A poisonous mutant huntingtin protein (mHTT) results from an HTT gene mutation that causes HD. This genetic mutation leads to neuronal dysfunction and eventual neurodegeneration. Moreover, the clinical manifestations of HD vary widely among individuals, both in terms of symptom onset and progression. Thus, complex disease pathophysiology is hampering the growth of the market.
The pandemic led to the suspension or delay of many clinical trials for Huntington’s Disease due to lockdowns, travel restrictions, and the reallocation of healthcare resources to address COVID-19. In addition, the global supply chain disruptions caused by the pandemic affected the availability of medications and medical supplies for HD patients. Thus, the COVID-19 pandemic had a negative impact on the market.
The Asia-Pacific region's nations are investing in expanding and modernizing its hospitals, clinics, and specialized treatment facilities. Better facilities and access to healthcare enable HD patients to receive sophisticated treatment choices, interdisciplinary care, and early diagnosis. Consequently, the Asia pacific region would acquire nearly 25% of the total market share by 2031. Genetic diversity within the Asia Pacific region provides unique opportunities for studying Huntington’s Disease genetics, disease variants, and population-specific factors influencing disease progression.
Huntington’s disease is caused by a mutation in the HTT gene, which produces an abnormal form of the huntingtin protein. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Additionally, Healthcare expenditure encompasses funding allocated to biomedical research, including neurodegenerative diseases like Huntington’s disease. Furthermore, investments in healthcare infrastructure, such as specialized clinics, research centers, and laboratory facilities, are essential for advancing HD research and treatment. Therefore, rising healthcare expenditures and investments are propelling the market’s growth.
However, A poisonous mutant huntingtin protein (mHTT) results from an HTT gene mutation that causes HD. This genetic mutation leads to neuronal dysfunction and eventual neurodegeneration. Moreover, the clinical manifestations of HD vary widely among individuals, both in terms of symptom onset and progression. Thus, complex disease pathophysiology is hampering the growth of the market.
The pandemic led to the suspension or delay of many clinical trials for Huntington’s Disease due to lockdowns, travel restrictions, and the reallocation of healthcare resources to address COVID-19. In addition, the global supply chain disruptions caused by the pandemic affected the availability of medications and medical supplies for HD patients. Thus, the COVID-19 pandemic had a negative impact on the market.
Driving and Restraining Factors
Drivers- Advancements in genetic research and biotechnology
- Rising healthcare expenditure and investments
- Increasing prevalence of Huntington’s disease (HD)
- Complex disease pathophysiology
- Limited treatment options
- Growing government initiatives
- Rise of telemedicine and digital health
- High development costs
- Ethical and genetic counseling issues
Drug Type Outlook
Based on drug type, the Huntington's Disease Treatment Market is divided into approved drugs and offlabel drugs. In 2023, the offlable drugs segment acquired 15.3% revenue share in the Huntington's Disease Treatment Market. Off-label drugs may offer potential benefits in managing specific symptoms of Huntington’s Disease, such as psychiatric symptoms (e.g., depression, anxiety), irritability, and cognitive impairment. Healthcare providers may explore off-label options to alleviate these challenging symptoms that significantly impact patient quality of life.Distribution Channel Outlook
On the basis of distribution channel, the Huntington's Disease Treatment Market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. In 2023, the drug stores & retail pharmacies segment attained 32.7% revenue share in the Huntington's Disease Treatment Market. Retail pharmacies stock a variety of medications used to manage symptoms associated with Huntington’s Disease, including medications for chorea (involuntary movements), psychiatric symptoms (e.g., depression, anxiety), and cognitive impairments.Age Outlook
By age, the Huntington's Disease Treatment Market is bifurcated into below 50 years and above 50 years. The above 50 segment held 43.3% revenue share in the Huntington's Disease Treatment Market in 2023. Huntington’s Disease can present with subtle or atypical symptoms in older adults, leading to delays in diagnosis. As awareness and diagnostic capabilities improve, more individuals above 50 years old may receive a diagnosis of HD, prompting the initiation of treatment and management strategies to address symptoms and optimize quality of life.Regional Outlook
Region-wise, the Huntington's Disease Treatment Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 42% revenue share in the Huntington's Disease Treatment Market in 2023. North America has a relatively higher Huntington’s Disease prevalence than other regions. The disease is more commonly diagnosed among populations of European descent, which are prominent in North America. Also, the region is a global leader in biomedical research and pharmaceutical innovation.List of Key Companies Profiled
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Dr.Reddy’s Laboratories Ltd.
- Neurocrine Biosciences Inc.
- Pfizer, Inc.
- F.Hoffmann-La Roche Ltd.
Market Report Segmentation
By Drug Type- Approved Drugs
- Tetrabenazine
- Deutetrabenazine
- Offlabel Drugs
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Pharmacies
- Below 50 years
- Above 50 years
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Huntington’s Disease Treatment Market by Drug Type
Chapter 5. Global Huntington’s Disease Treatment Market by Distribution Channel
Chapter 6. Global Huntington’s Disease Treatment Market by Age
Chapter 7. Global Huntington’s Disease Treatment Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Neurocrine Biosciences Inc.
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd.
Methodology
LOADING...